Replies

Similar outcome, this time with Ivermectin.

https://freerepublic.com/focus/f-bloggers/4215547/posts

Patient Zero Comes Back From Stage Four Cancer: Was It Ivermectin?
Rescue with Michael Capuzzo ^ | 02/06/2024 | MARY BETH PFEIFFER
Posted on 2/6/2024, 11:16:58 PM by SeekAndFind

Paul Mann received chemotherapy and radiation treatments for metastatic prostate cancer. “It was just so hard,” he said. “Then I thought, I can’t give up. I have it written on my arm that I won’t.” He took ivermectin and supplements after traditional care and is in remission. (Photos from Paul Mann)

After ten rounds of radiation and six of chemotherapy, Paul Mann, fifty-five years old, wanted to know his chances. “You’re squeaking by day to day,” his doctor told him. It had been five months since his diagnosis. He was referred to a hospice service and seen by a minister.
Then something happened of which most end-of-the-line cancer patients can only dream.

Mann, a government intelligence analyst from Fenton, Missouri, received a call from a doctor he had heard about from a friend; the doctor had treated breast cancer for thirty years. They talked for three hours in calls that became a Tuesday routine. Early on, a drug named ivermectin came up. It was approved, had few side effects, and had been shown in laboratory and animal studies to kill several kinds of cancer cells.

Mann got some of it himself, making an eight-hour round-trip drive to Tennessee, the only state where ivermectin can be bought over-the-counter. He took it every day. And two months later, this man with almost no chance of survival was in remission.

“In Paul Mann’s case, the response to treatment after two months of ivermectin was nothing less than astonishing,” said Mann’s guardian angel, Dr. Kathleen Ruddy, a retired cancer surgeon and author of a book on breast cancer. “Off the charts astonishing.”

Mann may someday be called Patient Zero in a first-of-its-kind study, announced by the FLCCC Alliance at its conference today, to see if old drugs like ivermectin work for cancer. Dr. Paul Marik, FLCCC chief scientific officer, and Dr. Ruddy, who was trained at Memorial Sloan Kettering Cancer Center, will become partners in an “observational study” involving 500 patients and five clinics nationwide. The goal will be to learn if repurposed drugs improve five-year survival rates for several types of cancer, including breast, prostate, lung, and colorectal, an FLCCC press release states.

Dr. Ruddy did not treat Mann but rather talked a dying man through his options. In the same manner, patients in the new study will choose which FDA-approved drugs—like ivermectin, mebendazole, nitazoxanide and others—they want to use to treat their cancers, either along with or instead of traditional therapies. Their progress will be overseen and tracked by clinicians who will share anonymous patient information across sites in a collaboration to see what works.

Of prime importance, “If you have a look at the list of drugs, they are completely safe and devoid of significant side effects,” said Dr. Marik, who wrote a book on repurposing drugs for cancer. “That’s what oncologists don’t like.”

Indeed, the idea to challenge American cancer care with off-the-shelf drugs is, indisputably, a daring undertaking. That’s just one reason why it will be performed “methodically, impartially, and according to the highest standards of medical research,” Dr. Ruddy said.

“We must make sure this is absolutely above board because people are going to go after us furiously,” Dr. Marik told me.